Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/7949
|
| Title: | Targeting Akt signaling for treatment of advanced prostate cancer cells with caffeic acid phenethyl ester |
| Authors: | Chuu, CP;Lin, HP;Su, LC;Lin, CY;Huo, C;Kuo, YY;Chu, SC |
| Contributors: | Institute of Cellular and Systems Medicine;National Institute of Cancer Research |
| Abstract: | Prostate cancer is one of the most common non-cutaneous carcinomas of men in Western countries. More than 80% of patients die from prostate cancer bone metastases. Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, most prostate cancer patients receiving the androgen ablation therapy will ultimately develop recurrent, castration-resistant tumors within 1-3 years after treatment. The median overall survival time is 1-2 years after tumor relapse. Chemotherapy is usually applied for treatment of metastatic hormone-refractory prostate cancer. However, they showed little effect on prolonging survival. Undesired side effects of these chemotherapeutic agents include toxic deaths, strokes, thrombosis, neutropenia, edema, dyspnea, malaise, and fatigue. Combining chemotherapeutic drugs with natural compounds of anticancer activities may reduce the dosage of chemotherapeutic drugs needed. More than 80% of prostate tumors acquire mutation or deletion of tumor suppressor phosphatase and tensin homolog (PTEN), a negative regulator of PI3K/Akt signaling, indicating that inhibition of PI3K/Akt might be a potential therapy for advanced prostate tumors. Our observations indicated that caffeic acid phenethyl ester (CAPE) treatment suppressed proliferation of different prostate cancer cell lines as well as tumor growth of PC-3 xenograft. CAPE treatment disturbed cell cycle progression in human prostate cancer cells. CAPE decreased protein expression of cyclin D1, cyclin E, SKP2, c-Myc, Akt1, Akt2, Akt3, total Akt, mTOR, Bcl-2, Rb, as well as phosphorylation of Rb, ERK1/2, Akt, mTOR, GSK3α, GSK3β, PDK1. In contrast, CAPE increased protein expression of KLF6 and p21Cip1. Combination of CAPE with chemotherapeutic drugs produced synergistic suppression effects. Our studies indicated that CAPE treatment affects Akt signaling in prostate cancer cells and CAPE administration may thus serve as a potential adjuvant therapy for advanced prostate cancer. |
| Date: | 2012-12 |
| Relation: | Prostate Cancer Cells: Detection, Growth and Treatment. 2012 Dec:57-72. |
| Link to: | https://www.novapublishers.com/catalog/product_info.php?products_id=39452 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84895322242 |
| Appears in Collections: | [褚志斌] 圖書
[其他] 圖書
|
Files in This Item:
There are no files associated with this item.
|
All items in NHRI are protected by copyright, with all rights reserved.
|
